The latest price target for Twist Bioscience (NASDAQ:TWST) was reported by Scotiabank on February 4, 2025. The analyst firm set a price target for $62.00 expecting TWST to rise to within 12 months (a possible 49.33% upside). 22 analyst firms have reported ratings in the last year.

The latest analyst rating for Twist Bioscience (NASDAQ:TWST) was provided by Scotiabank, and Twist Bioscience maintained their sector outperform rating.

The last upgrade for Twist Bioscience Corp happened on January 17, 2024 when Goldman Sachs raised their price target to $45. Goldman Sachs previously had a neutral for Twist Bioscience Corp.

There is no last downgrade for Twist Bioscience.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Twist Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Twist Bioscience was filed on February 4, 2025 so you should expect the next rating to be made available sometime around February 4, 2026.

While ratings are subjective and will change, the latest Twist Bioscience (TWST) rating was a maintained with a price target of $54.00 to $62.00. The current price Twist Bioscience (TWST) is trading at is $41.52, which is out of the analyst’s predicted range.